Literature DB >> 21954411

Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis.

Hüseyin Saadettin Uslusoy1, Selim Giray Nak, Macit Gülten.   

Abstract

AIM: To evaluate certain anthropometric, clinical and laboratory features indicating liver fibrosis in nonalcoholic steatohepatitis and to establish the noninvasive markers for liver fibrosis.
METHODS: Eighty-one patients (40 male, 41 female) who were diagnosed with fatty liver by ultrasonographic examination and fulfilled the inclusion criteria participated in the study. Anamnesis, anthropometric, clinical and laboratory features of all cases were recorded and then liver biopsy was performed after obtaining patient consent. Steatosis, necroinflammation and liver fibrosis were examined according to age ≥ 45, gender, body mass index, central obesity, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 1, γ-glutamyltransferase (GGT)/ALT > 1, platelet count, insulin, c-peptide levels and the presence of hypertension, diabetes, hypertriglyceridemia and insulin resistance.
RESULTS: Eighty-one patients with non-alcoholic steatohepatitis (NASH) enrolled in the study. 69 of 81 patients were diagnosed with NASH, 11 were diagnosed with simple fatty liver and 1 was diagnosed with cirrhosis. AST/ALT > 1, GGT/ALT > 11, high serum ferritin and fasting insulin levels, the presence of diabetes, hypertension, hypertriglyceridemia and insulin resistance seemed to enhance the severity of steatosis, necroinflammation and fibrosis but these results were not statistically significant.
CONCLUSION: Liver steatosis and fibrosis can occur in individuals with normal weight. There was no significant concordance between severity of liver histology and the presence of predictors for liver fibrosis including metabolic risk factors.

Entities:  

Keywords:  Liver fibrosis; Nonalcoholic fatty liver disease; Predictors; Steatohepatitis

Year:  2011        PMID: 21954411      PMCID: PMC3180608          DOI: 10.4254/wjh.v3.i8.219

Source DB:  PubMed          Journal:  World J Hepatol


  67 in total

1.  Liver fibrosis in overweight patients.

Authors:  V Ratziu; P Giral; F Charlotte; E Bruckert; V Thibault; I Theodorou; L Khalil; G Turpin; P Opolon; T Poynard
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

2.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

3.  Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease.

Authors:  I R Willner; B Waters; S R Patil; A Reuben; J Morelli; C A Riely
Journal:  Am J Gastroenterol       Date:  2001-10       Impact factor: 10.864

4.  Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD.

Authors:  Hellan Kang; Joel K Greenson; Jason T Omo; Cewin Chao; Debra Peterman; Lilian Anderson; Laura Foess-Wood; Mary A Sherbondy; Hari S Conjeevaram
Journal:  Am J Gastroenterol       Date:  2006-10       Impact factor: 10.864

5.  Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.

Authors:  Nathalie C Leite; Cristiane A Villela-Nogueira; Vera L N Pannain; Adriana C Bottino; Guilherme F M Rezende; Claudia R L Cardoso; Gil F Salles
Journal:  Liver Int       Date:  2011-02-20       Impact factor: 5.828

6.  Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass.

Authors:  Camilo Boza; Arnoldo Riquelme; Luis Ibañez; Ignacio Duarte; Enrique Norero; Paola Viviani; Alejandro Soza; Jose Ignacio Fernandez; Alejandro Raddatz; Sergio Guzman; Marco Arrese
Journal:  Obes Surg       Date:  2005-09       Impact factor: 4.129

7.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

8.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

9.  [Clinical and histological features of non-alcoholic fatty liver disease].

Authors:  Jun-ping Shi; Yun-hao Xun; Chen-bo Hu; Li Zhang; Hong Liu; Guo-qiang Lou; Jian-gao Fan
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2009-11

10.  Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.

Authors:  S A Harrison; D Oliver; H L Arnold; S Gogia; B A Neuschwander-Tetri
Journal:  Gut       Date:  2008-04-04       Impact factor: 23.059

View more
  3 in total

1.  Interleukin-15 receptor α on hepatic stellate cells regulates hepatic fibrogenesis in mice.

Authors:  Jingjing Jiao; Kohtaro Ooka; Holger Fey; Maria Isabel Fiel; Adeeb H Rahmman; Kensuke Kojima; Yujin Hoshida; Xintong Chen; Tatiana de Paula; Diana Vetter; David Sastre; Ka Hin Lee; Youngmin Lee; Meena Bansal; Scott L Friedman; Miriam Merad; Costica Aloman
Journal:  J Hepatol       Date:  2016-05-03       Impact factor: 25.083

2.  Assessment of Lifestyle Factors Helps to Identify Liver Fibrosis Due to Non-Alcoholic Fatty Liver Disease in Obesity.

Authors:  Mari Lahelma; Panu K Luukkonen; Sami Qadri; Noora Ahlholm; Susanna Lallukka-Brück; Kimmo Porthan; Anne Juuti; Henna Sammalkorpi; Anne K Penttilä; Johanna Arola; Marju Orho-Melander; Hannele Yki-Järvinen
Journal:  Nutrients       Date:  2021-01-08       Impact factor: 5.717

3.  The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease.

Authors:  Halina Cichoż-Lach; Krzysztof Celiński; Beata Prozorow-Król; Jarosław Swatek; Maria Słomka; Tomasz Lach
Journal:  Med Sci Monit       Date:  2012-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.